SCHEMBL2986280

SCHEMBL2986280

CN(C)CC1(C)C(=O)NC(=O)N1CCNc1ncc(Br)c(-c2cc3ccccc3s2)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCI P41743 1/20 0.33
PRKCE Q02156 1/20 0.33
PRKCQ Q04759 1/20 0.33
PRKCZ Q05513 1/20 0.33
PRKCD Q05655 1/20 0.33
PRKD1 Q15139 1/20 0.33
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
IKBKG Q9Y6K9 1/20 0.32
MERTK Q12866 1/20 0.32
GRIN2B Q13224 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PIK3CG P48736 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2974918 0.91 JAK2 (0.33) PRKCQMERTKPIK3CDPIK3CAPIK3CB
SCHEMBL2981806 0.89 MERTK (0.32) IKBKBMERTKPIK3CDPIK3CAPIK3CB
SCHEMBL2975235 0.88 MERTK (0.34) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL2990338 0.82 PIP5K1C (0.37) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL2986348 0.82 PIP5K1C (0.36) PRKCQIKBKBCHUKIKBKGMERTK
SCHEMBL2986516 0.82 CCNC (0.34) PRKCQIKBKBCHUKIKBKGMERTK
SCHEMBL2980877 0.82 PIP5K1C (0.35) PRKCQIKBKBCHUKIKBKGMERTK
SCHEMBL2982366 0.81 MERTK (0.34) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL5147380 0.79 ALDH1A1 (0.40) IKBKBCHUKIKBKGMERTKPIK3CD
SCHEMBL5149156 0.79 MERTK (0.35) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 PRKD3 352/4885PRKCG 891/4885PRKCB 882/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 PRKD3 352/4885PRKCG 891/4885PRKCB 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.